In February 21st, according to the ” Chongqing Zhifei Biological Products Co.Ltd(300122) ” official account of WeChat, the recombinant New Coronavirus vaccine (CHO cell) was approved as a sequential (heterologous) booster for COVID-19 inactivated vaccine.
According to the sequential immunization strategy of COVID-19 virus vaccine, the COVID-19 virus inactivated vaccine of Beijing company, Beijing Kexing company and Chinese medicine Wuhan company can be vaccinated throughout the whole period for 6 months, and the 18 year old and above people who have completed homologous immunization have implemented the sequential immunization of New Coronavirus (CHO cell).
At present, through the sequential immunization strategy of New Coronavirus (CHO cell), New Coronavirus will enhance the effectiveness of the existing vaccine. It will provide a safe and effective solution for the prevalence of the COVID-19 mutation, further consolidate the effectiveness of COVID-19 vaccination, and build a universal immune barrier. It is of great significance to effectively curb the spread of covid-19 pneumonia.
Chongqing Zhifei Biological Products Co.Ltd(300122) said that the recombinant New Coronavirus vaccine (CHO cell) is a recombinant subunit vaccine developed by China Academy of Sciences microbiology Institute and Anhui Zhi Fei Long Ma Biological Pharmaceutical Co., Ltd., which is made from genetic engineering and expressed in the engineering cell to purify pathogen antigen protein, and has complete independent intellectual property rights. In March 2021, the vaccine was registered and listed in Uzbekistan, becoming the first recombinant subunit covid-19 vaccine registered and listed in the world.
The results of the international multicenter phase III clinical trial showed that after 18 years of age and above, 3 doses of recombinant New Coronavirus vaccine (CHO cells) were inoculated, and the protective efficacy of COVID-19 for any severity was 81.43%. The latest research shows that the vaccine can still provide good protection against the Omicron variant.
On February 21, Chongqing Zhifei Biological Products Co.Ltd(300122) (300122) was reported at 125.61 yuan, up 0.34%.
